Ironwood Capital Connecticut Portfolio Company IsoPlexis: Response noted in non-Hodgkin patients

By on , In the News

Reprinted from BioCT, June 22, 2018 IsoPlexis has announced the publication of clinical data demonstrating a significant association between the functionality of anti-CD19 CAR-T cell product before treatment, as defined by IsoPlexis’ Polyfunctional Strength Index (PSI), and the objective response in patients with non-Hodgkin lymphoma. “We were excited to collaborate on this groundbreaking research,” said […]